Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 41
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    El-Saifi, N. Moyle, W. Jones, C. and Tuffaha, H. 2016. Quetiapine safety in older adults: a systematic literature review. Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Issue. 1, p. 7.

    Rao, Ahsan Suliman, Amna Story, Giles Vuik, Sabine Aylin, PAUL and Darzi, ARA 2016. Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia. International Journal of Methods in Psychiatric Research,

    Correll, Christoph U. Joffe, Benjamin I. Rosen, Lisa M. Sullivan, Timothy B. and Joffe, Russell T. 2015. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry, Vol. 14, Issue. 1, p. 56.

    Jackson, John W. VanderWeele, Tyler J. Blacker, Deborah and Schneeweiss, Sebastian 2015. Mediators of First- Versus Second-generation Antipsychotic-related Mortality in Older Adults. Epidemiology, Vol. 26, Issue. 5, p. 700.

    Cipriani, Gabriele Danti, Sabrina Vedovello, Marcella Nuti, Angelo and Lucetti, Claudio 2014. Understanding delusion in dementia: A review. Geriatrics & Gerontology International, Vol. 14, Issue. 1, p. 32.

    Jackson, J. W. VanderWeele, T. J. Viswanathan, A. Blacker, D. and Schneeweiss, S. 2014. The Explanatory Role of Stroke as a Mediator of the Mortality Risk Difference Between Older Adults Who Initiate First- Versus Second-Generation Antipsychotic Drugs. American Journal of Epidemiology, Vol. 180, Issue. 8, p. 847.

    Trifiró, Gianluca Sultana, Janet and Spina, Edoardo 2014. Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies. Drug Safety, Vol. 37, Issue. 7, p. 501.

    Gustafsson, Maria Karlsson, Stig and Lövheim, Hugo 2013. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacology and Toxicology, Vol. 14, Issue. 1,

    Hsieh, Pei-Hua Hsiao, Fei-Yuan Gau, Susan Shur-Fen and Gau, Churn-Shiouh 2013. Use of Antipsychotics and Risk of Cerebrovascular Events in Schizophrenic Patients. Journal of Clinical Psychopharmacology, Vol. 33, Issue. 3, p. 299.

    Wu, Chi-Shin Wang, Sheng-Chang Gau, Susan Shur-Fen Tsai, Hui-Ju and Cheng, Yu-Cheng 2013. Association of Stroke with the Receptor-Binding Profiles of Antipsychotics—A Case-Crossover Study. Biological Psychiatry, Vol. 73, Issue. 5, p. 414.

    Chatterjee, Satabdi Chen, Hua Johnson, Michael L. and Aparasu, Rajender R. 2012. Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. Drugs & Aging, Vol. 29, Issue. 10, p. 807.

    Pratt, Nicole Roughead, Elizabeth E Salter, Amy and Ryan, Philip 2012. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Medical Research Methodology, Vol. 12, Issue. 1,

    Ihl, Ralf Frölich, Lutz Winblad, Bengt Schneider, Lon Burns, Alistair and Möller, Hans-Jürgen 2011. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. The World Journal of Biological Psychiatry, Vol. 12, Issue. 1, p. 2.

    Chahine, Lama M. Acar, Diler and Chemali, Zeina 2010. The Elderly Safety Imperative and Antipsychotic Usage. Harvard Review of Psychiatry, Vol. 18, Issue. 3, p. 158.

    Chan, Man-chak Chong, Catherine Shiu-yin Wu, Anna Ying-king Wong, Kai-choi Dunn, Eva Lai-wah Tang, Orlando Wai-nang and Chan, Wah-fat 2010. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. International Journal of Geriatric Psychiatry, Vol. 25, Issue. 4, p. 362.

    Gentile, Salvatore 2010. Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology, Vol. 212, Issue. 2, p. 119.

    Pratt, Nicole L. Roughead, Elizabeth E. Ramsay, Emmae Salter, Amy and Ryan, Philip 2010. Risk of Hospitalization for Stroke Associated with Antipsychotic Use in the Elderly. Drugs & Aging, Vol. 27, Issue. 11, p. 885.

    Sacchetti, Emilio Turrina, Cesare and Valsecchi, Paolo 2010. Cerebrovascular Accidents in Elderly People Treated with Antipsychotic Drugs. Drug Safety, Vol. 33, Issue. 4, p. 273.

    Benoît, M. Camus, E. Cnockaert, X. Nourashemi, F. Pancrazi, M. P. Plas, J. Agostino, M. I. Alexandra, J. -F. Beaufils, B. Cano, J. -P. Hazif-Thomas, C. Kruczek, B. Laurent, B. Michel, B. F. Nieoullon, A. Polydor, J. -P. Sarazin, M. and Jeandel, C. 2009. La prescription des antipsychotiques chez le sujet âgé. Les cahiers de l'année gérontologique, Vol. 1, Issue. 3, p. 149.

    List, Martin and Supprian, Tillmann 2009. Inadäquate Vokalisationen bei Demenzkranken. Zeitschrift für Gerontopsychologie & -psychiatrie, Vol. 22, Issue. 2-3, p. 111.


Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics

  • Sanford Finkel (a1), Chris Kozma (a2), Stacey Long (a3), Andrew Greenspan (a4), Ramy Mahmoud (a4), Onur Baser (a5) and Luella Engelhart (a6)
  • DOI:
  • Published online: 01 October 2005

Background:The possibility that low-dose antipsychotic treatment is associated with increased risk of cerebrovascular events (CVEs) in elderly patients with dementia has been raised. The objective was to determine whether risperidone is associated with an increased risk of CVEs relative to other commonly considered alternative treatments.

Methods:An analysis of Medicaid data from 1999 to 2002, representing approxi-mately 8 million enrollees from multiple states, was conducted. The primary outcome was the incidence of acute inpatient admission for a CVE within 3 months following initiation of treatment with atypical antipsychotics (risperidone, olanzapine, quetiapine, or ziprasidone), haloperidol, or benzo-diazepines.

Results:Descriptive analyses found similar rates of incident CVEs across evaluated agents. Multivariate analyses found no differences in comparisons of risperidone with olanzapine or quetiapine. Risperidone and other antipsychotics as a group were also not associated with a higher odds ratio (OR) of incident CVE than either haloperidol or benzodiazepines. With risperidone as the reference group: olanzapine, OR=1.05, 95% CI 0.63–1.73; quetiapine, OR=0.66, 95% CI 0.23–1.87; haloperidol, OR=1.91, 95% CI 1.02–3.60; benzodiazepines, OR=1.97, 95% CI 1.30–2.98. With benzodiazepines as the reference group, the OR of incident CVE for all antipsychotics as a class was 0.49, 95%CI 0.35–0.69.

Conclusions:This study found no significant difference in the incidence of CVEs between patients taking risperidone and those taking other atypical antipsychotics. Risperidone and all atypical antipsychotics were not associated with higher risk than two common treatment alternatives (haloperidol and benzodiazepines). These findings do not support the conclusion that risperidone is associated with a higher risk of CVE than other available treatment alternatives. The data also suggest that patient characteristics other than antipsychotic use are more significant predictors of CVEs. Given the relatively low rates of incident CVEs, a larger sample of patients with groups closely balanced on a wide spectrum of potential risk factors could provide a more precise assessment of risk.

Corresponding author
Correspondence should be addressed to: Luella Engelhart, Ortho-McNeil Janssen Scientific Affairs, L.L.C., 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, U.S.A. Phone: +1 609 730 3119; Fax: +1 609 730 2411.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *